← SynDRA
SIPONIMOD
SynDRA canonical compound SYN0036992 — structure-anchored drug synonym record
| Clinical phase | Launched |
|---|
| Approval status | Approved · Rx |
|---|
| Primary target(s) | S1PR1 | S1PR5 |
|---|
| Mechanism of action | sphingosine 1-phosphate receptor modulator |
|---|
| Indication | multiple sclerosis |
|---|
| Disease area | neurology/psychiatry |
|---|
All known targets
- S1PR1
- S1PR5
- S1PR2
- S1PR3
- S1PR4
Mechanisms of action (all sources)
- S1PR1 AGONIST
- Sphingosine 1-phosphate receptor Edg-1 agonist
- sphingosine 1-phosphate receptor modulator
- S1PR1 MODULATOR
- S1PR5 MODULATOR
Drug classes
- Immunologic Factors
- Immunosuppressive Agents
- Sphingosine 1 Phosphate Receptor Modulators
- Sphingosine 1-Phosphate Receptor Modulators
- Sphingosine 1-phosphate Receptor Modulator
ATC classes
- L04A · IMMUNOSUPPRESSANTS
Cross-references
Synonyms
- siponimod fumaric acid
- mayzent
- NVP-BAF312-NX
- BAF-312
- BAF312
- Mayzent
- BAF 312
- RR6P8L282I
- siponimodum
- RefChem:57741
- DTXCID0076338
- L04AA42
- BAF-312(SiponiMod)
- Siponimod [INN]
- Siponimod [WHO-DD]
- Siponimod [USAN]
- MFCD26142651
- BAF312 (Siponimod)
- C29H35F3N2O3
- UNII-RR6P8L282I
- J8C
- Siponimod (Standard)
- SIPONIMOD [MI]
- Siponimod (USAN/INN)
- BAF312 (Siponimod)?
- SCHEMBL641699
- GTPL9289
- orb1300798
- SCHEMBL29362334
- EX-A873
- Siponimod [USAN:INN:WHO-DD]
- GLXC-05932
- HMS5085P12
- WHO 9491
- BDBM50428142
- EBC-27261
- HY-12355R
- AKOS027254138
Reported adverse events
- Bradycardia
- Dizziness
- Headache
- Hypertension
- Infection
- Nausea
- Pain
- Pain in extremity
- Progressive multifocal leukoencephalopathy
- Seizure
- Bradyarrhythmia
- Fall
Look up SIPONIMOD in the interactive SynDRA portal →